3317612698 - 3319584817
Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.

Sarcomi dei tessuti molli ed ipertermia

ipertermia oncologica

Il presente studio clinico appare di grande interesse.
Si tratta di uno studio randomizzato multicentrico che compara l’impatto sulla recidiva locale da sarcoma dei tessuti molli ad elevata aggressività e sulla sopravvivenza globale dell’aggiunta alla chemioterapia neoadiuvante di ipertermia capacitiva profonda a radiofrequenza oncologica.
I Pazienti provengono da nove Centri terapeutici dislocati in diversi continenti.
Su entrambi gli elementi di studio (tasso di recidiva locale e sopravvivenza globale) l’aggiunta di ipertermia presenta un impatto positivo e significativo.

Dr. Carlo Pastore


JAMA Oncol. 2018 Feb 15. doi: 10.1001/jamaoncol.2017.4996. [Epub ahead of print]

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.

Issels RD1Lindner LH1Verweij J2Wessalowski R3Reichardt P4Wust P5Ghadjar P5Hohenberger P6Angele M7Salat C1Vujaskovic Z8Daugaard S9Mella O10Mansmann U11Dürr HR12Knösel T13Abdel-Rahman S1Schmidt M14Hiddemann W1Jauch KW7Belka C15Gronchi A16European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology.

Author information




Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment. Preoperative anthracycline plus ifosfamide chemotherapy improves outcome in common histological subtypes.


To analyze whether the previously reported improvement in local progression-free survival by adding regional hyperthermia to neoadjuvant chemotherapy translates into improved survival.


Open-label, phase 3 randomized clinical trial to evaluate the efficacy and toxic effects of neoadjuvant chemotherapy plus regional hyperthermia. Adult patients (age ≥18 years) with localized soft tissue sarcoma (tumor ≥5 cm, French Federation Nationale des Centers de Lutte Contre le Cancer [FNCLCC] grade 2 or 3, deep) were accrued across 9 centers (6, Germany; 1, Norway; 1, Austria; 1, United States) from July 1997 to November 2006. Follow-up ended December 2014.


After stratification for tumor presentation and site, patients were randomly assigned to either neoadjuvant chemotherapy consisting of doxorubicin, ifosfamide, and etoposide alone, or combined with regional hyperthermia.


The primary end point was local progression-free survival. Secondary end points included treatment safety and survival, with survival defined from date of randomization to death due to disease or treatment. Patients lost to follow-up were censored at the date of their last follow-up.


A total of 341 patients were randomized, and 329 (median [range] age, 51 [18-70] years; 147 women, 182 men) were eligible for the intention-to-treat analysis. By December 2014, 220 patients (67%; 95% CI, 62%-72%) had experienced disease relapse, and 188 (57%; 95% CI, 52%-62%) had died. Median follow-up was 11.3 years. Compared with neoadjuvant chemotherapy alone, adding regional hyperthermia improved local progression-free survival (hazard ratio [HR], 0.65; 95% CI, 0.49-0.86; P = .002). Patients randomized to chemotherapy plus hyperthermia had prolonged survival rates compared with those randomized to neoadjuvant chemotherapy alone (HR, 0.73; 95% CI, 0.54-0.98; P = .04) with 5-year survival of 62.7% (95% CI, 55.2%-70.1%) vs 51.3% (95% CI, 43.7%-59.0%), respectively, and 10-year survival of 52.6% (95% CI, 44.7%-60.6%) vs 42.7% (95% CI, 35.0%-50.4%).


Among patients with localized high-risk soft tissue sarcoma the addition of regional hyperthermia to neoadjuvant chemotherapy resulted in increased survival, as well as local progression-free survival. For patients who are candidates for neoadjuvant treatment, adding regional hyperthermia may be warranted.